Charles A. Kennedy, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: In a 9-year longitudinal study by Sepkowitz and colleagues, spontaneous pneumothorax developed in 20 of 1030 (2.0%) patients with the acquired immunodeficiency syndrome (AIDS) (1). The relative risk for pneumothorax was associated with prophylactic aerosolized pentamidine and previous episodes of Pneumocystis carinii pneumonia (1). Patients were initially randomized to receive 30, 45, or 60 mg of aerosolized pentamidine every 2 weeks using a Seimens microinhalation device (Seimens Corporation, Munich, Germany). Subsequently, all patients received 60 mg of aerosolized pentamidine using a different nebulizing device (Fisoneb, Fisons Pharmaceuticals, Rochester, New York). The authors do not provide specific
Kennedy CA. Pneumothorax in AIDS. Ann Intern Med. 1991;115:328–329. doi: 10.7326/0003-4819-115-4-328_2
Download citation file:
© 2019
Published: Ann Intern Med. 1991;115(4):328-329.
DOI: 10.7326/0003-4819-115-4-328_2
Infectious Disease.
Results provided by: